ReNerve kicks off IPO roadshow, points to market darling Orthocell

  • 📰 FinancialReview
  • ⏱ Reading Time:
  • 22 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 90%

Brasil Notícia Notícia

Brasil Últimas Notícias,Brasil Manchetes

ReNerve reckons its NervAlign Nerve Cuff is a lower cost, more effective and easier to use treatment for Peripheral Nerve Injury (PNI).

ASX aspirant ReNerve, which this week launched an investor roadshow to market its initial public offering, is hoping to mirror the success of the only other life-sciences stock on the local bourse.

The nerve-repair company plans to list in late November on the back of an approved product in the United States market. Lead manager Alpine Capital is seeking to raise as much as $7 million for an enterprise value of $20.3 million, according to a prospectus lodged with the corporate regulator.has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories.

 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 2. in BR

Brasil Últimas Notícias, Brasil Manchetes